相似文献
1
Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
Can Med Assoc J. 1972 Nov 4;107(9):851-5.
2
Cross-resistance to alkylating agents in multiple myeloma.
Cancer. 1983 Sep 1;52(5):786-9. doi: 10.1002/1097-0142(19830901)52:5<786::aid-cncr2820520505>3.0.co;2-h.
3
Treatment of plasma cell myeloma with cytotoxic agents.
Arch Intern Med. 1975 Jan;135(1):172-6.
4
Multiple myeloma. II. The value of melphalan.
S Afr Med J. 1974 May 18;48(24):1026-8.
5
Multiple myeloma without initial paraproteins.
Am J Med Sci. 1972 Oct;264(4):267-75. doi: 10.1097/00000441-197210000-00002.
6
Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Cancer Treat Rep. 1979 Aug;63(8):1265-9.
7
Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).
Cancer Chemother Rep. 1975 May-Jun;59(3):557-62.
8
Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.
JAMA. 1969 Feb 17;207(7):1328-34.
9
Multiple myeloma. A clinical review.
Med Clin North Am. 1975 Mar;59(2):375-86. doi: 10.1016/s0025-7125(16)32039-9.
10
Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
Mymensingh Med J. 2012 Jan;21(1):114-9.
引用本文的文献
1
Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation - a retrospective analysis.
Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):437-442. doi: 10.1016/j.htct.2020.07.007. Epub 2020 Sep 13.
2
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Br J Cancer. 1996 Mar;73(6):794-7. doi: 10.1038/bjc.1996.138.
3
Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients.
J Clin Pathol. 1981 May;34(5):455-63. doi: 10.1136/jcp.34.5.455.
4
Intensive chemotherapy for solid tumours--current clinical applications.
Cancer Chemother Pharmacol. 1982;9(3):127-33. doi: 10.1007/BF00257740.
5
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
Cancer Chemother Pharmacol. 1983;11(2):80-5. doi: 10.1007/BF00254250.
6
Blood and neoplastic diseases. Myelomatosis.
Br Med J. 1974 Nov 30;4(5943):520-2. doi: 10.1136/bmj.4.5943.520.
7
Development of drug resistance in a murine mammary tumour.
Br J Cancer. 1985 Dec;52(6):823-32. doi: 10.1038/bjc.1985.265.
8
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Invest New Drugs. 1987;5 Suppl:S41-6. doi: 10.1007/BF00207262.
9
Achievements of cancer chemotherapy.
J R Coll Physicians Lond. 1976 Oct;11(1):59-74.
10
Multiple myeloma.
J R Coll Physicians Lond. 1979 Jul;13(3):146-53.
本文引用的文献
1
Non-protein sulphydryl group in the original strain and sub-line of the ascites tumour resistant to alkylating reagents.
Nature. 1960 Jun 25;186:1059-60. doi: 10.1038/1861059a0.
2
MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS.
JAMA. 1964 Sep 7;189:758-62.
3
TUMOUR SULPHYDRYL LEVELS AND SENSITIVITY TO THE NITROGEN MUSTARD MEROPHAN.
Biochem Pharmacol. 1963 Aug;12:839-45. doi: 10.1016/0006-2952(63)90114-x.
4
Maximum utilization of the life table method in analyzing survival.
J Chronic Dis. 1958 Dec;8(6):699-712. doi: 10.1016/0021-9681(58)90126-7.
5
Melphalan in multiple myeloma.
Blood. 1967 Jul;30(1):74-83.
6
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
JAMA. 1969 Jun 2;208(9):1680-5. doi: 10.1001/jama.208.9.1680.
7
Differences in the in vivo alkylation and cross-linking of nitrogen mustard-sensitive and -resistant lines of Lettré-Ehrlich asites tumors.
Cancer Res. 1969 Jun;29(6):1184-94.
8
Permeability difference as a source of resistance to alkylating agents in Ehrlich tumor cells.
Biochem Biophys Res Commun. 1968 Aug 21;32(4):650-7. doi: 10.1016/0006-291x(68)90288-x.
9
Repair of alkylated DNA in mammalian cells.
Nature. 1968 Jun 8;218(5145):970-2. doi: 10.1038/218970a0.
10
Melphalan therapy for plasma cell myeloma.
Blood. 1968 Jan;31(1):1-10.
Zotero 插件